Who are Paclitaxel based chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo plus Docetaxel, Dose dense AC followed by T + trastuzumab, Ivermectin + colchicine, docetaxel and cisplatin, Paclitaxel, Epirubicin, nab-paclitaxel，Cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-based-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Paclitaxel based chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel based chemotherapy (Paclitaxel based chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 3 Taxane Microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel based chemotherapy (Paclitaxel based chemotherapy) — Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying and spreading.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel based chemotherapy TARGET	Paclitaxel based chemotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	phase 3	Taxane	Microtubules
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
Ivermectin + colchicine	Ivermectin + colchicine	Ain Shams University	marketed	Antiparasitic + anti-inflammatory combination	Glutamate-gated chloride channels (ivermectin); tubulin/microtubules (colchicine)
docetaxel and cisplatin	docetaxel and cisplatin	Sanofi	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)
Paclitaxel, Epirubicin	Paclitaxel, Epirubicin	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (taxane + anthracycline)	Microtubules (paclitaxel); Topoisomerase II and DNA (epirubicin)
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

Sanofi · 3 drugs in this class
Akeso · 1 drug in this class
Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Central European Society for Anticancer Drug Research · 1 drug in this class
Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Jina Pharmaceuticals Inc. · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel based chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-based-chemotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing